In addition to ALN-induced changes in F-actin organization in prostate cancer cells [6, 13], zoledronate has been demonstrated to inhibit the expression of alphavbeta3 and alphavbeta5 integrins in endothelial cells [41] and to induce detachment of prostate cancer cells in association with FAK dephosphorylation [42]. Here, PTK2 is linked to prostate carcinoma.